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Abstract
This paper brings attention to a case report of osteoporosis diagnosed in a 67-year-old female
due to a low trauma fracture. The individual was deemed high fracture risk, and unestablished in
primary care. The drug class of Selective Serotonin Reuptake Inhibitors (SSRIs) and their
recently identified risk of decreasing bone mass density, increasing osteoporosis, and ultimately
doubling fracture incidence will be explored. Current osteoporosis screening guidelines are
examined and criticized in relation to the presented evidence. Evidence based articles and up to
date practice recommendations were reviewed. The results of multiple meta-analyses concluded
that SSRIs have a significant negative impact on bone metabolism, increasing fracture risk. The
high rates of unscreened osteoporosis, the current prevalence of the disease, and the lack of
inclusion of SSRI use in the current fracture risk assessment prove significant clinical relevance
of the results found.
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The Increased Risk of Osteoporosis with Selective Serotonin Reuptake Inhibitor Use and
The Need for Adjusted Screening Methods
Osteoporosis is defined as a “chronic skeletal disease marked by microarchitectural
deterioration of the bone matrix and depletion of bone mineral density (BMD), with a
consequent increased risk for fragility fracture” (Fernandes, Hodge, Pasco, Berk & Williams,
2016). An article by Gillespie and Morin (2017) discusses the current disparities in osteoporosis
screening for women. A retrospective six-year study of over 1.6 million women over the age of
50 revealed that osteoporosis screening was low overall. Only 21.2% of women ages 50-64,
26.5% ages 65-79, and 12.8% ages 80 and above were appropriately screened (Gillespie &
Morin, 2017). This represents a clear discrepancy in osteoporosis screening.
Osteoporotic fractures in post-menopausal women currently have a higher incidence rate
than stroke, myocardial infarction, and breast cancer combined. Fractures occurring in the
osteoporotic population represent a financial public health issue as they increase disability and
mortality risk (Watts & Manson, 2017). The commonality of osteoporosis along with the current
disparities in screening creates an outrageous health care concern.
Current osteoporosis screening guidelines from the United States Preventative Services
Task Force (USPSTF) recommend screening women aged 65 years and older or in younger
women with an equivalent fracture risk. Up to Date (2017) advises to perform a fracture risk
assessment in all adults, post-menopausal women, men over 60, or any patient with a history of a
low trauma fracture. The fracture risk assessment was introduced in 2008 by the World Health
Organization (WHO), termed as the Fracture Risk Assessment Tool (FRAX). The FRAX
estimates the 10-year risk of a major osteoporotic fracture for an untreated patient using the sum
of clinical risk factors.

INCREASED OSTEOPOROSIS RISK WITH SSRI USE

5

Over the past two years, meta-analysis reviews have revealed that the use of SSRIs at
therapeutic levels for depression and anxiety have a negative effect on bone structure, decreasing
bone mineral density and increasing fracture risk (Bruyere & Reginster, 2015) (Fernandes,
Hodge, Pasco, Berk & Williams, 2016). Currently, the FRAX does not consider SSRI use in
calculating one’s fracture risk. This paper gives its readers the evidence to include SSRI use into
the fracture risk assessment, along with the importance of adjusted screening methods for the
SSRI population.
Background
A 67-year-old female presents for an 8-week post-operative follow up appointment for a
right hip replacement due to a total right hip fracture. She has little primary care history. She
displays high fracture risk qualities of post-menopausal age, current 1.5 ppd smoker with a 75pack year history, low body weight, and does not participate in weight bearing exercise. Per
patient report of the low trauma injury causing her fracture and additive risk factors, a dualenergy x-ray absorptiometry (DXA) scan was ordered, and revealed the diagnosis of
osteoporosis. The current screening guidelines previously stated by the USPSTF are in place
with a rationale that half of all post-menopausal women will experience an osteoporotic-related
fracture in their life (Gillespie & Morin, 2017). The previously stated screening disparities may
rise from the ill-defined wording and ambiguity of the current guidelines.
As formerly discussed, to calculate fracture risk, current practice guidelines listed in Up
To Date (2017) recommend using the FRAX assessment tool. The FRAX tool is meant to allow
providers the ability to assess fracture risk with or without bone mineral density information.
Clinical information used to assess risk include; age, gender, weight, height, previous fracture,
parent fractured hip, current smoking status, current glucocorticoid use or a history of more than
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a 3-month dose of prednisone 5mg/day, rheumatoid arthritis, secondary osteoporosis, alcohol use
of 3 or more units/day, and can consider femoral neck BMD. Secondary osteoporosis is present
when a patient has a disease strongly associated with osteoporosis. Stated on the FRAX
calculator, this includes “type I diabetes, osteogenesis imperfecta in adults, untreated long
standing hyperthyroidism, hypogonadism or premature menopause (<45 years of age), chronic
malnutrition, or malabsorption and chronic liver disease.” (Fracture Risk Assessment Tool,
http://www.shef.ac.uk/FRAX/index.aspx). SSRI use is not taken into account in any area of the
FRAX screening tool.
Recent reviews have looked at longitudinal, cross-sectional, prospective cohort, and
randomized controlled trials and have unanimously stated that SSRI use independently decreases
bone health, leading to increased developments of osteoporosis. Additionally, SSRIs
independently doubled the occurrence of fragility fractures associated with osteoporosis
(Fernandes et al, 2016). SSRIs are the first line therapy worldwide for treatment of depression,
mood, and anxiety disorders, especially in the older adult population due to the favorable adverse
effect profile (Bruyere & Reginster, 2015). With the evidence presented here and the high
prevalence of SSRI use, the absence of its inclusion in the Fracture Risk Assessment Tool
(FRAX) needs to be addressed.
The purpose of this report is to relate the defined terms and guidelines of osteoporosis to
recently studied SSRI effects on bone mass, and further, to identify current disparities in fracture
risk assessments and improve screening efforts related to osteoporosis.
Case Report
A 67-year-old female presents for an 8-week post-operative appointment for a right hip
replacement due to a total right hip fracture. The total right hip fracture occurred from a fall in
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the bath tub. The patient states she is feeling O.K. today, and denies any concerns or complaints.
She has little primary care history, and inconsistent health care visits. She would like to discuss
establishing care at this clinic. Patient is Caucasian. Past medical history of hypertension,
depression, and breast cancer of the right breast. Denies any history of fractures. Denies any drug
allergies. She is widowed with three grown children. Currently smoking 1.5 ppd for 50 years
(75 pack years). Rarely uses alcohol and does not exercise. She is retired, and states she is
relatively inactive. She denies being up to date on any of her screenings besides a mammogram
in 2016 that was unremarkable. Current medications are Lisinopril 10mg po daily and arimidex
1mg po daily. Today’s vital signs are: BP: 132/70, HR: 78, RR:16, O2: 96%, Weight: 121lbs.
She denies any pain today. She does occasionally experience mild pain at home, mostly
in the mornings, and takes 650mg of Tylenol every 6 hours as needed. She states she graduated
from her assigned physical therapy post-surgery. She denies any fevers, chills, redness,
drainage, or swelling at the surgical site.
In an in-depth review of systems, she further denies headache, changes in vision, recent
illness, shortness of breath, chest pain, heart palpitations, muscle weakness, numbness or
tingling, nausea, vomiting, diarrhea, dysuria, polyuria, or any other pain unrelated to her hip.
She denied any issues with her mood now, but does have a history of taking sertraline (Zoloft)
for depression symptoms in the past.
Physical exam is unremarkable. Patient is good spirits, and happy with the results of her
recovery. She is moving all extremities equally, and transferring well onto exam table. No
grimacing or guarding noted. Surgical site is well approximated, and healing appropriately. No
redness, drainage, bruising or swelling noted to surgical site. She is alert and cooperative
throughout exam. No signs of distress. Non-diaphoretic. Head is normocephalic and
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atraumatic. No adenopathy. Normal S1, S2 heart sounds with regular rate and rhythm. Radial and
distal pulses +2. Capillary refill less than 3 seconds. No peripheral edema or swelling noted.
Breath sounds auscultated are clear and equal throughout all lung fields. Good air exchange
noted throughout.
Following the physical exam, we discussed future screenings and interventions that she
should have at a follow up appointment to establish primary care. These included a
colonoscopy, follow up mammogram, a low dose CT scan given her smoking history, up to date
immunizations, a complete metabolic panel, CBC, lipid profile, and TSH. It was explained to
the patient that a dual energy x-ray absorptiometry (DEXA scan) should be complete today. This
is needed imaging to evaluate her bone density. Given the nature of her fracture, and
osteoporosis risk factors, it is suspected that she has osteoporotic changes in her bones.
The DEXA scan resulted with a T score of -4.1 of the lumbar spine, and of -2.1 in the
femoral neck. These scores are significant, and the conclusion is a diagnosis of osteoporosis
with a high fracture risk. These results were reviewed with the patient. We discussed associated
risk factors of smoking, post-menopausal age, low body weight, taking an aromatase inhibitor,
and her sedentary lifestyle. A treatment plan was created with the patient and includes a
smoking cessation plan, weight bearing exercises for 30 minutes 3 times a week, begin taking
1000mg of a calcium supplement and 800 units of vitamin daily, and to take alendronate
(Fosamax) 70mg PO once a week. Education was provided on adverse drug reactions and the
importance of taking Fosamax with a large glass of water, 30 minutes before the first meal or
medication of the day. Additionally, avoid laying down for 30 minutes after taking. Instructed
patient to follow up with dentist annually. The patient verbalized understanding, and agreed with
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plan of care. She denied any further questions or concerns. She will follow up in two weeks for
an annual physical and to schedule additional primary care screenings.
Literature Review
The above case report presents a high-risk osteoporosis patient. Due to her lack of
regular visits with a provider, she did not have the opportunity to be appropriately screened prior
to fracture occurrence. As previously stated, a 2017 study revealed that only 21.2% of women
ages 50-64, 26.5% ages 65-79, and 12.8% ages 80 and above were appropriately screened for
osteoporosis (Gillespie & Morin, 2017). This data shows that even post-menopausal women
visiting their provider regularly, are not being appropriately screened for osteoporosis. Had this
patient been established in primary care, or had regular clinic visits, she may have had a “26.5%”
chance of being appropriately screened. Gillespie and Morin (2017) show a clear gap in
preventative care related to osteoporosis. Additionally, recent studies reveal a strong relationship
between depression, SSRI use, decreased bone density, and increased fracture occurrence. This
additional information would put this patient in an even higher baseline risk category for
osteoporosis. A literature review was conducted on the current evidence available on
osteoporosis screening, and the relationship between SSRIs and bone density. By implementing
appropriate and early screening methods, high risk osteoporosis patients have the opportunity for
early interventions and lifestyle management. Early interventions may decrease fracture
occurrence, ultimately improving patient quality of life, and driving down health care costs.
Current Screening and Management Recommendations
Screening for osteoporosis is mildly unclear, and autonomy is given to the provider to
assess risk factors on an individual basis. This may account for the low screening numbers in
postmenopausal women. Kleerekoper (2015), writes for the Up To Date practice guidelines
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stating, “Screening for osteoporosis involves fracture risk assessment and measurement of bone
mineral density (BMD). We recommend assessing risk factors for fracture in all adults,
especially postmenopausal women, men over 60 years, and in any individual who experiences a
fragility or low-trauma fracture.” Here the author’s recommendations differ from the USPSTF
recommendations for screenings for all adults versus adults over 65 years of age. Risk factors
are listed as: advanced age, previous fracture, long term use of glucocorticoid therapy, low body
weight (less than 127lb), family history of hip fracture, cigarette smoking, and excess alcohol
intake. It is recommended to use clinical information to assess fracture risk using the FRAX tool
previously discussed. USPSTF recommends screening women aged 65 years and older or in
younger women with an equivalent fracture risk. As more findings arise showing adverse effects
on bone health from a variety of risk factors, risk assessments should be completed in all adults.
USPSTF and Up to Date (2015), suggest bone mineral density (BMD) testing using a
DEXA scan in women 65 years of age and older, and in younger postmenopausal women with
clinical risk factors for fracture. BMD testing in men is only suggested if they present with
clinical risk factors of low bone mass and fracture.
Up to Date bases these recommendations off a well-designed randomized control trial
that concluded that screening is directly related to a reduced fracture risk. The published trial
used 4800 postmenopausal women (45-54 years), and randomly placed them in either a BMD
screening or no screening group. After an average of nine years, 37-52% of screened women
reported using hormone replacement therapy, or other osteoporosis medications compared to 2245% of unscreened women (Barr, Stewart, Togerson & Reid, 2010). This study showed that
screening for osteoporosis increases the percentage of women that initiated anti-osteoporotic
medications as an early intervention.
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The management guidelines discussed address the microarchitectural disruption that
occurs in osteoporosis, as well as lifestyle regimens to prevent, or treat bone loss. Intaking
enough calcium and vitamin D daily prevents excessive bone resorption. Supplementation
guidelines are based off meta-analysis reports. Combined intake amounts from diet and
supplementation should total at 1200mg of calcium, and 800 international units of vitamin D
daily. Guidelines further recommend a total intake of 1000mg of calcium, and 600 international
units of vitamin D for premenopausal women, or men with osteoporosis (Rosen, 2016, as
presented in Up to Date). The U.S. Food and Drug Administration (FDA) currently has four
medications approved to improve bone strength. Options include oral bisphosphonates weekly
or monthly, or nonoral bisphosphonates administered biannually or annually. Bisphosphonates,
supplementation, and lifestyle management to reduce the risk of fracture is the first line
treatment regimen for osteoporosis (Watts & Manson, 2017). Early interventions of these
management guidelines would benefit patients screened as high fracture risk.
Pathophysiology of Bone Metabolism and the SSRI impact
Osteoblasts, osteoclasts, and osteocytes are the three major cells types that create the
bone. Continuous bone remodeling is done as osteoclasts perform bone resorption. This is
followed by bone generation of the osteoblasts, which create the osteocytes that interconnect and
insert themselves into the bone matrix. This process is how bone mass is preserved, and how it
remodels in response to physical stressors (Fernandes et al., 2016). Altering this bone
remodeling process is how serotonin disrupts the bone matrix.
Serotonin is commonly known to be produced in the brain, having a centrally inhibitory
effect on the sympathetic nervous system. In the treatment of depression and anxiety, SSRIs
increase the level of serotonin in the synapse for the post-synaptic cell to uptake. This is done by
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inhibiting the reuptake of serotonin of the pre-synaptic cell. Unknown to common belief,
serotonin is also produced peripherally. Highest concentrations of peripherally produced
serotonin are found in the gastrointestinal tract, but the osteoclasts in the bone microenvironment
release peripheral serotonin as well. This peripheral serotonin from osteoclasts has a direct
effect on osteoblastic serotonin receptors, inhibiting bone remodeling. In this manner,
osteoclast-derived serotonin act as paracrine and autocrine to regulate the process of bone
remodeling. In the instance of SSRI use, elevated serotonin levels are induced both centrally and
peripherally (Fernandes et al., 2016). These peripheral elevated serotonin levels are increasing
the signaling to the osteoblasts to inhibit bone formation, decreasing bone mass, and increasing
the risk of osteoporosis and fracture.
Depression and Osteoporosis.
Depression as a disease has been previously associated with bone deterioration, and
increased fracture risk. Like osteoporosis, depression is a highly prevalent disease that is
lifelong and debilitating. The associated lack of motivation, low energy, and impaired cognitive
functioning all impact one’s quality of life. Besides their association, the relationship between
depression and osteoporosis remains unclear. More recently, there has been strong evidence to
support the hypothesis that the chemical imbalance of depression alters bone metabolism,
increasingly when SSRI treatment is used. In a review of current studies, even after known risk
factors for osteoporosis were eliminated, clinical depression and depressive symptoms were
shown to remain negatively associated with decreased bone mass. The evidence supports that
negative implications on bone mass occur at the onset of depressive symptoms, not just later in
life (Fernandes et al., 2016). A review revealed that people with depression versus without
exhibited “lower bone mass at the spine, hip, forearm, with a stronger association observed for
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pre-menopausal than for post-menopausal women” (Fernandes et al., 2016, p.23). While
studying SSRI use and it’s indication on bone health, it is imperative to address the independent
association of depression and decreased bone health.
Furthermore, a study was completed to study the effects on anxiety disorders and bone
health. Anxiety and depression are now commonly thought to be on a continuum. With
depression associated with decreased bone health in the past, this study revealed anxiety
disorders impact bone metabolism negatively as well. High levels of stress seen in anxiety
disorders decrease osteocalcin levels that are naturally increased during bone construction, which
decreasing bone density. While studying SSRI use to treat anxiety disorders, the authors
concluded a significant negative relationship between duration of SSRI treatment and BMD
values (Ak et al., 2015).
Details of SSRI use.
Selective serotonin reuptake inhibitors are the most used antidepressants throughout the
world. They make up 60% of all antidepressants prescribed. A Canadian cohort study over 5
years studied 5000 adults over 50, and reveals that daily use of SSRIs doubled the risk of
fragility fractures, even after confounding variables were adjusted. Additionally, it found that
the fracture risk was dose dependent, but that intermittent users risk was equal to daily users.
Further supporting the results, another cohort study of over 7000 adults over age 55, revealed
that current SSRI user’s risk of vertebral fractures was over double the risk of past SSRI users
and tricyclic antidepressants users. This study also clarified that SSRI use was an independent
risk factors of depressive symptoms. Additional meta-analysis only potentiates the argument
that SSRI use has negative implications on bone metabolism, increasing risk of osteoporotic
fractures (as stated in Fernandes et al., 2016).
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The peripheral serotonin receptors and transporters in bone cells are directly where
changes in serotonin impact bone homeostasis. In a trial on mice, by disrupting the serotonin
transporter gene, or by inhibiting the serotonin transporter gene by pharmacologic use, as in
SSRIs, resulted in low bone mass. These results were similar in growing and adult mice
(Fernandes et al., 2016). The data generated from multiple animal trials presents evidence that
serotonin plays a direct role in bone homeostasis, and that the inhibition of the serotonin
transporter through SSRI use has a direct anti-anabolic effect on bone metabolism (Fernandes et
al., 2016). These animal studies prove the relationship between SSRIs and bone health even in
the absence of other human osteoporosis risk factors.
Bruyere and Reginster (2015) looked at fracture outcomes through a review of the
literature that further backs the presented data, stating there is a direct relationship with SSRI use
and decreased BMD. Their analysis performed a quantitative assessment of the relationship
between SSRIs and fracture risk. Results were unanimous and showed that SSRI use was
associated with an “increase in fractures of all types, non-vertebral, hip, and spine fractures”.
(Bruyere & Reginster, 2015, p.66). They discussed that the increased risk of fracture has been
supported by “several distinct populations, using various study designs with bone density, bone
loss, or fractures as outcomes…these results are consistent after adjustments for confounding
variables such a age, body mass index, lifestyle factors, and history of fractures.” (p.66). The
results of this systematic review present substantial strength in the argument that SSRIs need to
be more routinely included in fracture risk assessments.
Additionally, Bruyere and Reginster (2015) found that the strength of the association of
SSRIs and decreased BMD differs based on SSRI dose, duration, time, age, or sex. They go on
to state a further meta-analysis has been done taking these factors into account and that the
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“strength of the association decreased with a longer window of SSRI administration” (Bruyere &
Reginster, 2015, p.67). Additional cohort studies presented here support that the highest risk of
fracture is found at SSRI initiation-8 months, remaining elevated until 18 months. A 10-year
Canadian cohort study revealed that higher doses of SSRIs at base line was associated with high
fracture risk. Of equal importance, a Dutch case control study showed a significant association
between the discontinuation of SSRI use and the rapid decreased risk of fracture as well (Bruyere
& Reginster, 2015). More studies need to be performed to define the details of how SSRI use
effect bone health, but there is sufficient evidence of their direct relationship.
The 10-year Canadian cohort study presented in a review by Bruyere and Reginster
(2015) was also looked at in depth for this literature review. Interestingly, the use of serotonin
and noradrenaline reuptake inhibitors (SNRIs) was also studied. These were found to elevate
risk of fracture as well as SSRIs (Moura, Bernatsky, Abrahamowicz, et al, 2014). In relation to
osteoporotic changes, this remains a clinically relevant area of study along with SSRIs prescribed
for depression. SNRIs are commonly used for depression and vasomotor symptom control in
menopausal women, who are already entering a higher fracture risk population.
Results and Recommendations the Literature.
With the current presented evidence, The Study of Osteoporotic Fractures have deemed
SSRI use an independent risk factor from depressive symptoms for fractures. Their studies
concluded this from unexpected findings, and have since stated that treating depression with
SSRIs intensifies the original risk of fracture from depressive symptoms. Individuals already at
an increased risk of compromised bone density, due to clinical depression, are being put at an
even greater risk through SSRI treatment. Final recommendations from the evaluated literature
concluded that timely and accurate musculoskeletal evaluations need to be done for patients of
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current or potential SSRI use. Further, serial evaluations with DEXA scans, early initiation of
anti-osteoporotic medications, and lifestyle management should be implemented in individuals
who are at an increased risk at baseline (Fernandes et al., 2016).
Bruyere and Reginster (2015) address the issue that SSRI use is not included in the
FRAX assessment scoring. They recommend that osteoporosis management be initiated for the
SSRI population. If not to be included in the FRAX scoring, this may be done on an individual
level. With the presented evidence, it is apparent that there needs to be a discussion between
providers and patients to educated SSRI uses that they may need to be monitored for bone health
complications.
Further, Hant and Bolster (2016) conclude in their research that SSRIs on a list of
medications that may harm bone. They recommend that health care providers closely monitor
the bone density of individuals on any glucocorticoids, proton pump inhibitors, aromatase
inhibitors, certain antiepileptic medications, and selective serotonin reuptake inhibitors. By
closely monitoring these patients, osteoporotic prevention treatment can be initiated as needed.
Warden and Fuchs (2016), skeptically look at recent meta-analyses on SSRIs and
fractures. Their findings were that these studies report a 70% increase in fracture risk when
taking an SSRI. Conversely, the authors here feel recent meta-analyses were “observational and
limited in their ability to establish causality” (p.211). After using the Bradford Hill criteria to
rule out a weak association between SSRI and fractures, they did conclude a strong and
consistent relationship between SSRIs and fractures. Warden and Fuchs (2016) demonstrated
that although a strong relationship is present, many studies have limitations and confounding
variables that remain a concern. Even with limitations preventing them from completely
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accepting the results, they do recommend bone density testing and interventions for SSRI users
presenting with additional risk factors.
Premenopausal versus postmenopausal women
Premenopausal fracture occurrence is much lower, and not related to BMD as fractures
are in postmenopausal women. Because of this, postmenopausal diagnostic criteria and
treatment guidelines cannot apply to this population. Screening in this population is up to the
provider, and performed on an independent basis. Current best practice guidelines notify
providers that it may be appropriate to screen for premenopausal osteoporosis if any of the
following occur; a low trauma fracture from standing height or less, causes of estrogen
deficiency, drugs including glucocorticoids, anticonvulsants, antidepressants, and high doses of
steroids, and similar risk factors to the postmenopausal population (Becker, 2017, as stated in Up
to Date). Providers must be proactive in their risk assessment. The responsibility of identifying
risk factors in premenopausal women, screening for osteoporosis, and early interventions truly
falls on individual providers.
Conclusion and Clinical Practice Proposal
The presented evidence proposes a strong association between SSRI use and
osteoporosis, independent of other variables. Although more randomized controlled trials may
be needed to strengthen the evidence, and decrease the limitations of the studies, the presence of
a negative association is clear through this literature review.
Aside from SSRI implications on bone health, osteoporosis screening numbers need to be
improved in primary care. Screening guidelines may need to be altered to become more specific,
urging providers of its importance. Including the use of SSRIs in the FRAX calculator or
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flagging providers to assess bone health before prescribing an SSRI would be beneficial to
patient outcomes.
Learning Points
•

Providers should understand the potential implications of SSRIs on bone health

•

Assessing bone health risk factors at all ages is a crucial component to preventative care

•

High risk osteoporotic fracture patients should have an in-depth bone health assessment
completed before starting an SSRI, this may include a DEXA scan and screening before
age 65. Early anti-osteoporotic medications should be initiated as needed.
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